Skip to main content

Table 3 Most frequent (≥ 1.0%) treatment-emergent adverse events (randomized safety population) from the open-label PULSAR trial

From: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

 

Number (%) of patients with adverse events

 

Rosuvastatin 10 mg (n = 505)

Atorvastatin 20 mg (n = 491)

Any adverse event

139 (27.5)

128 (26.1)

Myalgia

24 (4.8)

13 (2.6)

Urinary tract infection

13 (2.6)

16 (3.3)

Headache

8 (1.6)

7 (1.4)

Nausea

4 (0.8)

9 (1.8)

Bone pain

8 (1.6)

3 (0.6)

Muscle cramp

5 (1.0)

3 (0.6)

Peripheral edema

3 (0.6)

5 (1.0)

Back to article page

Trials

ISSN: 1745-6215